OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
OKYO Pharma LimitedNASDAQ: OKYO
Other Current Liabilities · Q2 FY2026 · quarter ended Sep 2025
Other current liabilities turns positive
Q2 FY2026 other current liabilities was $7.72M, compared with -$313.91K a year earlier. Over 3 fiscal years it compounded at +203.5% a year.
Context
- Other current liabilities amounted to 166.3% of total assets at the end of Q2 FY2026, up 155.2 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +2559.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 9.04M USD
- Year-over-year change
- +27.3%
- 4-year CAGR
- +58.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 9.04M | +27.3% |
| FY2024 | 2024-03-31 | 7.1M | +449.7% |
| FY2023 | 2023-03-31 | 1.29M | +299.6% |
| FY2022 | 2022-03-31 | 323.06K | -77.4% |
| FY2021 | 2021-03-31 | 1.43M | — |
Other Current Liabilities vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's Sep 2025 other current liabilities of $7.72M is the 3rd highest of the 10 companies compared; the peer median is $880.67K.
- Its year-over-year change of +2559.5% is the highest of 5, against a peer median of -18.6%.
- Other current liabilities amounts to 166.3% of total assets for OKYO, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $18.82M | — | +243.1% | 7.4% | |
| Mar 2026 | $18.45M | — | -8.5% | 8.5% | |
| Sep 2025 | $7.72M | +2559.5% | +203.5% | 166.3% | |
| Mar 2026 | $2.29M | -57.4% | +4.8% | 1.1% | |
| Mar 2026 | $2.03M | — | +28.2% | 9.4% | |
| Mar 2026 | $880.67K | +20.3% | — | 0.9% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $778K | +48.5% | +26.2% | 0.6% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | -$3K | -125.0% | — | 0.0% | |
| Peer median (excluding OKYO) | $880.67K | -18.6% | +26.2% | 0.9% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.5K | 883.44K | 980.08K | 580.94K | 1.89M |
| Inventory | 34 | (1.49K) | 170.31K | 0 | 0 |
| Other Current Assets | 71.75K | 1.49K | (170.31K) | 0 | 0 |
| Total Current Assets | 6.99M | 4.3M | 5.2M | 1.54M | 3.68M |
| Property, Plant & Equipment (Net) | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Total Assets | 7.09M | 4.3M | 5.2M | 1.54M | 3.68M |
| Account Payables | 210.99K | 517.67K | 1.02M | 6.13M | 7.9M |
| Short-term Debt | 34.14K | 0 | 2.22M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.43M | 323.06K | 1.29M | 7.1M | 9.04M |
| Total Current Liabilities | 1.71M | 1.35M | 7.26M | 7.42M | 9.23M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 64.61K | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M |
| Common Stock | 0 | 123.98M | 0 | 143.11M | 0 |
| Retained Earnings | (99.4M) | (112.43M) | (125.7M) | (142.52M) | (143.02M) |
| Accumulated OCI | 12.82M | (11.01M) | (7.74M) | (11.31M) | (11.47M) |
| Other Stockholders Equity | (1) | 2.41M | 173 | 4.84M | 2.23M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 5.32M | 2.95M | (2.05M) | (5.88M) | (5.55M) |
| Total Debt | 98.76K | 0 | 2.22M | 0 | 0 |
| Net Debt | (6.79M) | (2.7M) | (1.83M) | (826.85K) | (1.56M) |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.